Exploring Treatment Options in Fabry Disease to Address Management Gaps and Improve Patient Outcomes

Program Description

Fabry disease is a rare, X-linked, lysosomal storage disease caused by a deficiency in the lysosomal enzyme α-galactosidase (α-GAL). α-Gal A is responsible for the breakdown of glycolipids, specifically globotriaosylceramide (GL-3 or Gb3). This enzyme deficiency results in a continuous build-up of GL-3/Gb3 and related glycolipids in the body’s cells, leading to cell abnormalities and organ dysfunction that affects small blood vessels, the heart, and kidneys. Enzyme replacement therapy has been shown to decrease disease complications and slow progression, but its frequent administration and adverse reactions present therapeutic challenges for patients. Pharmacists in specialty practice settings are well positioned to facilitate access to emerging drug therapies and provide support to the multidisciplinary care team by helping navigate treatment selection, monitoring and managing drug-drug interactions, and providing guidance for dose adjustments. This webinar will provide an introduction to Fabry disease with a look at the role of adjunctive and emerging therapies. Educational points for pharmacists to share with patients regarding goals of treatment, adverse effects, and preparation and administration of drug therapies will also be reviewed.

Target audience: Health-system, managed care, retail, and specialty pharmacists

Type of activity: Application
Release date: January 9, 2023
Expiration date: January 9, 2024

Time to complete activity: 1.25 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate the pathophysiology, phenotypes, and clinical manifestations of Fabry disease
• Explore the efficacy and safety of current and emerging drug therapies for Fabry disease
• Determine evidence-based strategies for treatment as new data become available
• Identify methods to overcome treatment challenges in Fabry disease and implement individualized care strategies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hour (0.125 CEU) under the ACPE universal activity number 0290-0000-23-005-H01-P. The activity is available for CE credit through January 9, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Lunawati L. Bennett, MS, PhD, PharmD, FACN

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms